Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment
暂无分享,去创建一个
Yao Liu | Xianbo Wang | Yuxin Li | D. Xue | Jialiang Chen | L. Tao | Qun Zhang | B. Zhu | Shuaishuai Niu | Xue Yang | Le Sun | Rui Wang | F. Gao | Bingbing Zhu | Dongying Xue | Rui Wang
[1] M. Yuen,et al. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis , 2017, World journal of gastroenterology.
[2] G. Hirschfield,et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.
[3] J. Reguła,et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.
[4] Fengchun Zhang,et al. Therapeutic advances for primary biliary cholangitis: the old and the new , 2016, European journal of gastroenterology & hepatology.
[5] S. Milani,et al. Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[6] P. Invernizzi,et al. Making Sense of Autoantibodies in Cholestatic Liver Diseases. , 2016, Clinics in liver disease.
[7] I. Mackay,et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. , 2015, Journal of hepatology.
[8] V. Wong,et al. New simple prognostic score for primary biliary cirrhosis: Albumin‐bilirubin score , 2015, Journal of gastroenterology and hepatology.
[9] T. Saibara,et al. Autoantibody status and histological variables influence biochemical response to treatment and long‐term outcomes in Japanese patients with primary biliary cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[10] L. Cui,et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis , 2015, Alimentary pharmacology & therapeutics.
[11] K. Lindor,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.
[12] K. Lindor,et al. Primary biliary cirrhosis , 2003, The Lancet.
[13] A. Burroughs,et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.
[14] K. Lindor,et al. The Natural History of Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.
[15] E. Atkinson,et al. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients , 2014, Journal of Gastroenterology.
[16] A. Burroughs,et al. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study , 2013, Alimentary pharmacology & therapeutics.
[17] B. Liu,et al. Early biochemical response to ursodeoxycholic acid and long‐term prognosis of primary biliary cirrhosis: Results of a 14‐year cohort study , 2013, Hepatology.
[18] G. Alexander,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.
[19] K. Hino,et al. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis. , 2013, Internal medicine.
[20] C. Selmi,et al. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases , 2012, Expert review of gastroenterology & hepatology.
[21] V. Novack,et al. Primary biliary cirrhosis in Southern Israel: a 20 year follow up study. , 2012, European journal of internal medicine.
[22] R. Poupon. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.
[23] O. Chazouilleres,et al. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.
[24] A. Takaki,et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid , 2011, Journal of gastroenterology and hepatology.
[25] Y. Hiasa,et al. Biochemical response to ursodeoxycholic acid predicts long‐term outcome in Japanese patients with primary biliary cirrhosis , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.
[26] R. Chapman,et al. 28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC , 2011 .
[27] Shou-Dong Lee,et al. Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis , 2009, Journal of clinical gastroenterology.
[28] K. V. van Erpecum,et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.
[29] M. Kaplan,et al. Primary biliary cirrhosis , 1998, Hepatology.
[30] F. Lammert,et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.
[31] Y. Chrétien,et al. Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.
[32] B. Hansen,et al. Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.
[33] J. Rodés,et al. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.
[34] F. Carrat,et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. , 2005, Gastroenterology.
[35] E. Dickson,et al. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) , 1978, Virchows Archiv A.
[36] T. Therneau,et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.
[37] P. Grambsch,et al. Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.
[38] F. Schaffner,et al. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. , 1979, Gut.